Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia

被引:76
作者
Shapiro, Susan E. [1 ,2 ]
Phillips, Emma [3 ]
Manning, Richard A. [1 ,2 ]
Morse, Colin V. [4 ,5 ]
Murden, Sherina L. [4 ,5 ]
Laffan, Michael A. [1 ,2 ]
Mumford, Andrew D. [4 ,5 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Med, Ctr Haematol,Div Expt Med, London W12 0NN, England
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, London W12 0NN, England
[3] Univ Hosp NHS Fdn Trust, Dept Haematol, Bristol, Avon, England
[4] Univ Bristol, Bristol Heart Inst, Bristol, Avon, England
[5] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
dysfibrinogenaemia; fibrin polymerization; prothrombin time; coagulation disorder; bleeding; HUMAN FIBRINOGEN; CRYSTAL-STRUCTURE; BOVINE THROMBIN; POLYMERIZATION; PEPTIDE; DIAGNOSIS; CLEAVAGE; CHAIN;
D O I
10.1111/bjh.12085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heritable dysfibrinogenaemia (HD) is a rare qualitative disorder of fibrinogen (FGN). To better describe the clinical, laboratory and genotypic spectrum of HD, we evaluated 35 subjects identified at two UK centres using laboratory criteria. 12/35(34%) subjects with HD experienced bleeding (bleeding score >1 at any site), 3/35(9%) thrombosis and 20/35(57%) were asymptomatic. Amongst subjects with bleeding, symptoms were typically mild, at one anatomical site and seldom occurred after invasive procedures. All subject showed dry clot weight within or above laboratory reference interval (median 3.2 g/l; range 1.95.1), reduced Clauss fibrinogen (median 0.52 g/l; range 0.211.3), and prolonged thrombin (median 30.7 s; range 21.345.7) and reptilase (median 42.0 s; range 20.068.0) times. In all subjects, the prothrombin time ratio (PTR), determined by Sysmex CA-1500 coagulometer and Innovin activator, was abnormal (median 1.42; range 1.221.61). The activated partial thromboplastin time ratio and PTR with other coagulometers and activators were comparatively insensitive to HD. All subjects with HD harboured heterozygous candidate nucleotide variations within known hotspots in the FGN genes. The HD variants identified in this cross-sectional study seldom have significant clinical manifestations and show similar laboratory features irrespective of genotype. Selection of coagulometer and PT activator may markedly affect the detection of new HD cases using coagulation screening tests.
引用
收藏
页码:220 / 227
页数:8
相关论文
共 30 条
[1]   ABNORMAL POLYMERIZATION AND NORMAL BINDING OF PLASMINOGEN AND T-PA IN 3 NEW DYSFIBRINOGENAEMIAS - BARCELONA-III AND BARCELONA-IV (GAMMA-ARG 275-]HIS) AND VILLAJOYOSA (GAMMA-ARG 275-]CYS) [J].
BORRELL, M ;
GARI, M ;
COLL, I ;
VALLVE, C ;
TIRADO, I ;
SORIA, JM ;
SALA, N ;
MUNOZ, C ;
OLIVER, A ;
GARCIA, A ;
FONTCUBERTA, J .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (03) :198-206
[2]   Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 val->Asp) [J].
Brennan, SO ;
Hammonds, B ;
George, PM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2854-2858
[3]   Bβ 14 Arg → Cys variant dysfibrinogen and its association with thrombosis [J].
Castaman, G ;
Ghiotto, R ;
Tosetto, A ;
Rodeghiero, F .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) :409-410
[4]  
Cunningham MT, 2002, ARCH PATHOL LAB MED, V126, P499
[5]   Crystal structure of fragment double-D from human fibrin with two different bound ligands [J].
Everse, SJ ;
Spraggon, G ;
Veerapandian, L ;
Riley, M ;
Doolittle, RF .
BIOCHEMISTRY, 1998, 37 (24) :8637-8642
[6]  
Hanss M, 2001, ANN NY ACAD SCI, V936, P89
[7]   Clinical and biological features of 3 cases of hypofibrinogenemia associated with three different mutations (γAla341Thr, BβTyr326Cys and AαAsp496Asn) [J].
Hanss, Michel ;
Chevreaud, Caroline ;
French, Patrick ;
Negrier, Claude ;
de Mazancourt, Philippe .
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (03) :689-691
[8]  
HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P151
[9]  
Hayes T, 2002, ARCH PATHOL LAB MED, V126, P1387
[10]   Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias [J].
Hill, M. ;
Dolan, G. .
HAEMOPHILIA, 2008, 14 (05) :889-897